GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » ARYA Sciences Acquisition Corp III (NAS:ARYA) » Definitions » ROE %

ARYA Sciences Acquisition III (ARYA Sciences Acquisition III) ROE % : -4.90% (As of Mar. 2021)


View and export this data going back to 2020. Start your Free Trial

What is ARYA Sciences Acquisition III ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ARYA Sciences Acquisition III's annualized net income for the quarter that ended in Mar. 2021 was $-7.08 Mil. ARYA Sciences Acquisition III's average Total Stockholders Equity over the quarter that ended in Mar. 2021 was $144.35 Mil. Therefore, ARYA Sciences Acquisition III's annualized ROE % for the quarter that ended in Mar. 2021 was -4.90%.

The historical rank and industry rank for ARYA Sciences Acquisition III's ROE % or its related term are showing as below:

ARYA's ROE % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.65
* Ranked among companies with meaningful ROE % only.

ARYA Sciences Acquisition III ROE % Historical Data

The historical data trend for ARYA Sciences Acquisition III's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYA Sciences Acquisition III ROE % Chart

ARYA Sciences Acquisition III Annual Data
Trend Dec20
ROE %
-

ARYA Sciences Acquisition III Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21
ROE % - -282.35 -0.87 -0.97 -4.90

Competitive Comparison of ARYA Sciences Acquisition III's ROE %

For the Shell Companies subindustry, ARYA Sciences Acquisition III's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARYA Sciences Acquisition III's ROE % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, ARYA Sciences Acquisition III's ROE % distribution charts can be found below:

* The bar in red indicates where ARYA Sciences Acquisition III's ROE % falls into.



ARYA Sciences Acquisition III ROE % Calculation

ARYA Sciences Acquisition III's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income (A: Dec. 2020 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=/( (+)/ )
=/
= %

ARYA Sciences Acquisition III's annualized ROE % for the quarter that ended in Mar. 2021 is calculated as

ROE %=Net Income (Q: Mar. 2021 )/( (Total Stockholders Equity (Q: Dec. 2020 )+Total Stockholders Equity (Q: Mar. 2021 ))/ count )
=-7.076/( (145.237+143.468)/ 2 )
=-7.076/144.3525
=-4.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2021) net income data. ROE % is displayed in the 30-year financial page.


ARYA Sciences Acquisition III  (NAS:ARYA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-7.076/144.3525
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.076 / 0)*(0 / 150.679)*(150.679 / 144.3525)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0438
=ROA %*Equity Multiplier
=N/A %*1.0438
=-4.90 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-7.076/144.3525
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-7.076 / -7.076) * (-7.076 / -7.12) * (-7.12 / 0) * (0 / 150.679) * (150.679 / 144.3525)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9938 * N/A % * 0 * 1.0438
=-4.90 %

Note: The net income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


ARYA Sciences Acquisition III ROE % Related Terms

Thank you for viewing the detailed overview of ARYA Sciences Acquisition III's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYA Sciences Acquisition III (ARYA Sciences Acquisition III) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
51 Astor Place, 10th Floor, New York, NY, USA, 10003
Website
ARYA Sciences Acquisition Corp III is a blank check company.
Executives
Adam Leo Stone director, 10 percent owner, officer: Chief Executive Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Michael Seth Altman director, 10 percent owner, officer: Chief Financial Officer C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Arya Sciences Holdings Iii 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Saqib Islam director ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219
Bradley L Campbell director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Konstantin Poukalov officer: Chief Business Officer C/O KADMON HOLDINGS, LLC, 450 E 29TH STREET, NEW YORK NY 10016